Chobanian AV, Bakris GL, Black HR, et al; the National High Blood Pressure Education Program Coordinating Committee. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206 52. 8.1.5. BP Goal for Patients With Hypertension S8.1.5-1. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels updated overview and meta-analyses of ran- domized trials. J Hypertens. 2016;34:613 22. S8.1.5-2. Xie X, Atkins E, Lv J, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet. 2016;387:435 43. S8.1.5-3. Verdecchia P, Angeli F, Gentile G, et al. More versus less intensive blood pressure-lowering strategy: cumulative evidence and trial sequential analysis. Hypertension. 2016;68:642 53. S8.1.5-4. Bangalore S, Toklu B, Gianos E, et al. Optimal systolic blood pres- sure target after SPRINT: insights from a network meta-analysis of randomized trials. Am J Med. 2017;30:707 19.e8. Whelton et al 2017 High Blood Pressure Clinical Practice Guideline e93 S8.1.5-5. Bundy JD, Li C, Stuchlik P, et al. Systolic blood pressure reduc- tion and risk of cardiovascular disease and mortality: a systematic review and network meta-analysis. JAMA Cardiol. 2017;2:775 81. S8.1.5-6. Julius S, Nesbitt SD, Egan BM, et al. Feasibility of treating pre- hypertension with an angiotensin-receptor blocker. N Engl J Med. 2006;354:1685 97. S8.1.5-7. Lawes CMM, Bennett DA, Lewington S, et al. Blood pressure and coronary heart disease: a review of the evidence. Semin Vasc Med. 2002;2:355 68. S8.1.5-8. Lonn EM, Bosch J, Lopez-Jaramillo P, et al. Blood-pressure lower- ing in intermediate-risk persons without cardiovascular disease. N Engl J Med. 2016;374:2009 20. S8.1.5-9. Neaton JD, Grimm RH Jr, Prineas RJ, et al. 